NewGen BioPharma Corp.: 10-Q/A filed 2013-06-27
What NewGen BioPharma Corp. reported in its quarterly report amendment filed 2013-06-27 (fiscal Q2 2013): 14 published measures, 47 facts as tagged in accession 0001165527-13-000591.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2013-06-27
- Fiscal period
- fiscal Q2 2013
- Accession
- 0001165527-13-000591 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NewGen BioPharma Corp. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-04-30 | 16,864 | USD | |
| At 2012-10-31 | 1,473 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-04-30 | 25,749 | USD | |
| At 2012-10-31 | 14,896 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-04-30 | -8,885 | USD | |
| At 2012-10-31 | -13,423 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-04-30 | 16,864 | USD | |
| At 2012-10-31 | 925 | USD | |
| At 2012-04-30 | 6,766 | USD | |
| At 2011-10-31 | 17,582 | USD | |
| At 2010-02-24 | 0 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-02-01 to 2013-04-30 | -7,296 | USD | 89 |
| 2012-11-01 to 2013-04-30 | -11,462 | USD | 181 |
| 2010-02-25 to 2013-04-30 | -42,885 | USD | 1161 |
| 2012-02-01 to 2012-04-30 | -6,520 | USD | 90 |
| 2011-11-01 to 2012-04-30 | -10,079 | USD | 182 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-11-01 to 2013-04-30 | 0 | USD | 181 |
| 2010-02-25 to 2013-04-30 | 2,342 | USD | 1161 |
| 2011-11-01 to 2012-04-30 | 0 | USD | 182 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-04-30 | 0 | USD | |
| At 2012-10-31 | 548 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-04-30 | 16,864 | USD | |
| At 2012-10-31 | 925 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-02-01 to 2013-04-30 | 7,296 | USD | 89 |
| 2012-11-01 to 2013-04-30 | 11,462 | USD | 181 |
| 2010-02-25 to 2013-04-30 | 42,885 | USD | 1161 |
| 2012-02-01 to 2012-04-30 | 6,520 | USD | 90 |
| 2011-11-01 to 2012-04-30 | 10,079 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-04-30 | 9,000,000 | shares | |
| At 2012-10-31 | 9,000,000 | shares |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-02-01 to 2013-04-30 | 1,698 | USD | 89 |
| 2012-11-01 to 2013-04-30 | 1,821 | USD | 181 |
| 2010-02-25 to 2013-04-30 | 5,855 | USD | 1161 |
| 2012-02-01 to 2012-04-30 | 950 | USD | 90 |
| 2011-11-01 to 2012-04-30 | 1,716 | USD | 182 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-02-01 to 2013-04-30 | 255 | USD | 89 |
| 2012-11-01 to 2013-04-30 | 548 | USD | 181 |
| 2010-02-25 to 2013-04-30 | 2,342 | USD | 1161 |
| 2012-02-01 to 2012-04-30 | 293 | USD | 90 |
| 2011-11-01 to 2012-04-30 | 586 | USD | 182 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-11-01 to 2013-04-30 | 0 | USD | 181 |
| 2010-02-25 to 2013-04-30 | 0 | USD | 1161 |
| 2011-11-01 to 2012-04-30 | 0 | USD | 182 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-11-01 to 2013-04-30 | 16,000 | USD | 181 |
| 2010-02-25 to 2013-04-30 | 34,000 | USD | 1161 |
| 2011-11-01 to 2012-04-30 | 0 | USD | 182 |
| 2011-02-01 to 2011-02-28 | 18,000 | USD | 28 |
Inspect the source
- Entity
- NewGen BioPharma Corp. / CIK 0001537274
- Captured
- SEC response SHA-256
d7f303f92ebc51b5c84b0c93fdae7cea7702fb134ae32e28604cb4d616f0316f
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001537274.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))